Viking Therapeutics Inc logo

Viking Therapeutics Inc

NAS:VKTX (USA)  
$ 74.31 +5.45 (+7.91%) 10:08 PM EST
At Loss
P/B:
8.77
Volume:
3.51M
Avg Vol (2M):
7.62M
Also Trade In:
Volume:
3.51M
At Loss
Avg Vol (2M):
7.62M

Business Description

Description
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Name Current Vs Industry Vs History
Cash-To-Debt 815.39
Equity-to-Asset 0.97
Debt-to-EBITDA -0.01
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 81.16
9-Day RSI 64.76
14-Day RSI 58.75
6-1 Month Momentum % 736.32
12-1 Month Momentum % 313.45

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 29.48
Quick Ratio 29.48
Cash Ratio 29.38

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -11
Shareholder Yield % -7.86